Finance

Lists
BH3:ETR
PTC Therapeutics, Inc.
€64.32
0.00%
(0.00) 1D
Aug 12, 5:35:53 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BH3...
Mkt. cap
5.99B
Avg. vol.
7.00
Volume
0.00
52-wk high
€78.18
52-wk low
€59.76
No. of employees
991
Mkt. cap
5.99B
Avg. vol.
7.00
Volume
0.00
52-wk high
€78.18
52-wk low
€59.76
No. of employees
991
News stories
From web sources and news partners
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
211.01M
164.68M
272.55M
360.52M
Cost of goods sold
115.94M
140.08M
129.70M
119.07M
Cost of revenue
115.94M
140.08M
129.70M
119.07M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
84.05M
96.87M
86.18M
80.63M
Operating expense
91.58M
106.22M
97.76M
92.47M
Total operating expenses
207.52M
246.30M
227.46M
211.54M
Operating income
3.49M
-81.62M
45.09M
148.98M
Other non operating income
102.00K
-7.65M
-1.00M
35.00K
EBT including unusual items
-23.07M
-139.08M
-2.46M
97.54M
EBT excluding unusual items
-31.40M
-150.16M
-3.55M
100.93M
Income tax expense
-38.97M
-4.12M
347.00K
14.05M
Effective tax rate
168.89%
2.96%
-14.09%
14.40%
Other operating expenses
-
-
-
-
Net income
15.90M
-134.96M
-2.81M
83.50M
Net profit margin
7.53%
-81.96%
-1.03%
23.16%
Earnings per share
0.19
-1.80
-0.03
0.92
Interest and investment income
19.09M
2.14M
17.98M
18.12M
Interest expense
-51.68M
-57.32M
-67.02M
-66.60M
Net interest expenses
-32.59M
-55.19M
-49.03M
-48.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
14.60M
-68.72M
60.50M
164.85M
Gain or loss from assets sale
53.00K
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps